Moreover, CAPR currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on four factors related to earnings estimates. Given an ...

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics ...

Our analysis of options history for Capricor Therapeutics CAPR revealed 8 unusual trades. Delving into the details, we found 25% of traders were bullish, while 62% showed bearish tendencies.

Inc.’s stock price changed recently Upgrades and downgrades for CAPR from analysts CAPR’s stock price momentum as measured by ...

CAPR has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $77.00 price target on shares of Capricor Therapeutics in a report on Thursday ...

CAPRICOR THERAPEUTICS ($CAPR) posted quarterly earnings results on Wednesday, March 19th. The company reported earnings of -$0.16 per share, beating estimates of -$0. ...

To get a sense of who is truly in control of Capricor Therapeutics, Inc. (NASDAQ:CAPR), it is important to understand the ownership structure of the business. And the group that holds the biggest ...

Capricor Therapeutics (CAPR) released expectation-beating results for the fourth quarter, sending the shares up over 5% in aftermarket trading. This comes on the heels of the company achieving a ...

Capricor Therapeutics (CAPR) announced long-term data from its ongoing HOPE-2 open label extension clinical trial, demonstrating the potential ...